{
    "nct_id": "NCT03289741",
    "official_title": "A Pilot Study To Evaluate Patient Experience With the Somatostatin Analogs Octreotide Long Acting Release and Lanreotide During the Treatment of Advanced, Nonfunctional, Well Differentiated Neuroendocrine Tumors",
    "inclusion_criteria": "* Willing and able to provide written informed consent for the trial\n* ≥ 18 years of age\n* Histologically- or cytologically- confirmed locally advanced or metastatic WDNET\n* SSA therapy is recommended by physician for disease management, and has not yet begun\n* ECOG performance status of 0, 1, or 2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Currently participating in a study of an investigational agent\n* Prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study Day 1 or not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent\n\n  *Note: Subjects with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study\n* No concurrent chemotherapy or targeted small molecule therapy\n* If received major surgery, not recovered adequately from the toxicity and/or complications from the intervention prior to starting the study\n* Known additional malignancy that is progressing or requires active treatment\n* Active infection requiring systemic therapy\n* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial",
    "miscellaneous_criteria": ""
}